Skip to main
CYRX
CYRX logo

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc. is positioned favorably within the life sciences sector, benefiting from the increasing acceptance and commercialization of cell and gene therapies, which are expected to drive both commercial revenue and clinical trial activity steadily. The growth in gene therapy programs across all development stages, particularly in oncology and rare diseases, suggests a robust pipeline that fosters optimism regarding future revenue streams. Additionally, CryoPort's diverse geographical presence, with a significant revenue base in the Americas, provides a solid foundation for continued expansion in this evolving market.

Bears say

CryoPort Inc. faces significant financial headwinds, evidenced by a persistent decline in start-up funding within the life sciences sector, which may impact overall market activity and growth potential. Additionally, the company’s APCA segment is experiencing a slowdown in demand for MVE freezers, highlighting a potential decrease in revenue generation capabilities. Overall, these factors contribute to a concerning outlook for CryoPort's financial performance as it navigates challenging market conditions.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.